News & Events about Uniqure Nv.
Globe Newswire
3 months ago
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and ...
Globe Newswire
3 months ago
~ Achieved U.S. and European Commission marketing approvals of first and only gene therapyfor adults with hemophilia B ~ ~ Advancing development of AMT-130 for patients with Huntingtons disease clinical update from U.S. Phase I/II trial expected in second quarter 2023 ~ ~Hosted virtual investor ...
Globe Newswire
3 months ago
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for prophylactic therapy and generate elevated and sustained factor IX levels for years after a one-time infusion...
Globe Newswire
5 months ago
If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia BLEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients ...
CSL's Novel Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment CSL's Novel Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Demonstrates Durable...